よむ、つかう、まなぶ。
65歳以上の成人に対する肺炎球菌ワクチン接種に関する考え方（第7版） (21 ページ)
出典
| 公開元URL | |
| 出典情報 | 65歳以上の成人に対する肺炎球菌ワクチン接種に関する考え方（第7版）（9／30）《日本呼吸器学会》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
conjugate vaccine in Japanese adults aged ≥65 years: subgroup analysis
of a randomized phase III Trial (PNEU-AGE). Jpn J Infect Dis.
2022;75:575-82.
17.Kobayashi M, et al. Use of 15-valent pneumococcal conjugate vaccine
and 20-valent pneumococcal conjugate vaccine among US adults: updated
recommendations of the advisory committee on immunization practice
(ACIP)–United States, 2022. Morb Mortal Wkly Rep. 2022;71:109–17.
18.Cannon K, et al. A trial to evaluate the safety and immunogenicity of
a 20-valent pneumococcal conjugate vaccine in populations of adults 65
years of age with different prior pneumococcal vaccination. Vaccine.
2021;39:7494-502.
19.Essink B, et al. Pivotal phase 3 randomized clinical trial of the
safety, tolerability, and immunogenicity of 20-valent pneumococcal
conjugate vaccine in adults aged 18 years. Clin Infect Dis.
2022;75:390-8.
20.Haranaka M, et al. A phase 3 randomized trial of the safety and
immunogenicity of 20-valent pneumococcal conjugate vaccine in adults
60 years of age in Japan, South Korea, and Taiwan. Vaccine.2024;
42:1071-7.
21.Centers for Disease Control and Prevention. 2016–2021 Serotype data
for invasive pneumococcal disease cases by age group from active
bacterial core surveillance(https://data.cdc.gov/Public-HealthSurveillance/2016-2021-Serotype-Data-for-Invasive-Pneumococcal-/qvzbqs6p/about_data)
22.小児・成人の侵襲性肺炎球菌感染症の疫学情報
(https://ipd-
information.com/adult/overview/)
23.Platt HL, et al. Safety, tolerability, and immunogenicity of an adult
pneumococcal conjugate vaccine, V116(STRIDE–3): a randomized, double-
21
of a randomized phase III Trial (PNEU-AGE). Jpn J Infect Dis.
2022;75:575-82.
17.Kobayashi M, et al. Use of 15-valent pneumococcal conjugate vaccine
and 20-valent pneumococcal conjugate vaccine among US adults: updated
recommendations of the advisory committee on immunization practice
(ACIP)–United States, 2022. Morb Mortal Wkly Rep. 2022;71:109–17.
18.Cannon K, et al. A trial to evaluate the safety and immunogenicity of
a 20-valent pneumococcal conjugate vaccine in populations of adults 65
years of age with different prior pneumococcal vaccination. Vaccine.
2021;39:7494-502.
19.Essink B, et al. Pivotal phase 3 randomized clinical trial of the
safety, tolerability, and immunogenicity of 20-valent pneumococcal
conjugate vaccine in adults aged 18 years. Clin Infect Dis.
2022;75:390-8.
20.Haranaka M, et al. A phase 3 randomized trial of the safety and
immunogenicity of 20-valent pneumococcal conjugate vaccine in adults
60 years of age in Japan, South Korea, and Taiwan. Vaccine.2024;
42:1071-7.
21.Centers for Disease Control and Prevention. 2016–2021 Serotype data
for invasive pneumococcal disease cases by age group from active
bacterial core surveillance(https://data.cdc.gov/Public-HealthSurveillance/2016-2021-Serotype-Data-for-Invasive-Pneumococcal-/qvzbqs6p/about_data)
22.小児・成人の侵襲性肺炎球菌感染症の疫学情報
(https://ipd-
information.com/adult/overview/)
23.Platt HL, et al. Safety, tolerability, and immunogenicity of an adult
pneumococcal conjugate vaccine, V116(STRIDE–3): a randomized, double-
21